Article Text

Download PDFPDF

Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication
  1. W K Leung1,
  2. S-R Lin2,
  3. J Y L Ching1,
  4. K-F To3,
  5. E K W Ng4,
  6. F K L Chan1,
  7. J Y W Lau4,
  8. J J Y Sung1
  1. 1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
  2. 2Department of Gastroenterology, The Third Hospital of Peking University, Beijing, China
  3. 3Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China
  4. 4Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
  1. Correspondence to:
    Dr J Sung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, 30-32, Ngan Shing Street, Shatin, Hong Kong;


Background and aim: Gastric intestinal metaplasia (IM) is generally considered to be a precancerous lesion in the gastric carcinogenesis cascade. This study identified the risk factors associated with progression of IM in a randomised control study.

Subjects and methods: A total of 587 Helicobacter pylori infected subjects were randomised to receive a one week course of anti-Helicobacter therapy (omeprazole, amoxicillin, and clarithromycin (OAC)) or placebo. Subjects underwent endoscopy with biopsy at baseline and at five years. Severity of IM was graded according to the updated Sydney classification and progression was defined as worsening of IM scores at five years in either the antrum or corpus, or development of neoplasia. Backward stepwise multiple logistic regression was used to identify independent risk factors associated with IM progression.

Results: Of 435 subjects (220 in the OAC and 215 in the placebo group) available for analysis, 10 developed gastric cancer and three had dysplasia. Overall progression of IM was noted in 52.9% of subjects. Univariate analysis showed that persistent H pylori infection, age >45 years, male subjects, alcohol use, and drinking water from a well were significantly associated with IM progression. Duodenal ulcer and OAC treatment were associated with a reduced risk of histological progression. Progression of IM was more frequent in those with more extensive and more severe IM at baseline. With multiple logistic regression, duodenal ulcer (odds ratio (OR) 0.23 (95% confidence interval (CI) 0.09–0.58)) was found to be an independent protective factor against IM progression. Conversely, persistent H pylori infection (OR 2.13 (95% CI 1.41–3.24)), age >45 years (OR 1.92 (95% CI 1.18–3.11)), alcohol use (OR 1.67 (95% CI 1.07–2.62)), and drinking water from a well (OR 1.74 (95% CI 1.13–2.67)) were independent risk factors associated with IM progression.

Conclusion: Eradication of H pylori is protective against progression of premalignant gastric lesions.

  • IM, intestinal metaplasia
  • GA, glandular atrophy
  • OAC, omeprazole, amoxicillin, and clarithromycin
  • OR, odds ratio
  • intestinal metaplasia
  • randomised trial
  • Helicobacter pylori
  • gastric cancer
  • prevention
View Full Text

Statistics from


    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles